IN THE UNITED STATES PATENT AND TRADEMARK OFFICE (Attorney Docket No.: 02-414-A1)

In re Application of:)
)
Varghese John) Examiner: Sahar Javanmard
)
Serial No.: 10/517,979)
) Art Unit: 1617
Filed: December 19, 2005)
) Confirmation No.: 1935
For: Methods Of Treating)
Alzheimer's Disease Using)
Aryl Alkanoic Acid Amides)

RESPONSE TO THE RESTRICTION REQUIREMENT MAILED DECEMBER 28, 2007

Commissioner for Patents P. O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

This paper is responsive to the Restriction Requirement mailed December 28, 2007, in the subject application.

Elections of a compound species and a disease species from within claim 1 are required.

With respect to a compound species, Applicants elect the compound of Example 1 on page 123. That compound is named 2(R,S)-Methyl-4(S)-hydroxy-5(S)-amino-7(S)-isopropyl-8-(p-tert-butylphenyl)-octanoic acid (N-butyl)amide hydrochloride and can be represented by the following formula:

The elected species can be defined in terms of the variables in Claim 1 as follows:

 R_1 , R_2 , and R_4 are all hydrogen;

 R_3 is t-butyl;

X is methylene;

R₅ is isopropyl;

R₆ is amino;

 R_7 is methyl; and

 R_8 is butyl.

The claims that read on the compound species identified above are claims 1, 2, 5, 6, 23, and 25.

With respect to a disease from the list in claim 1, Applicants elect Alzheimer's disease.

The pending claims that read on the species of Alzheimer's disease are claims 1-7, 23, 25, and 27.

The Applicants invite the Examiner to contact the Applicants' undersigned representative at (312) 913-2136 if the Examiner believes that this would expedite prosecution of this application.

Respectfully submitted,

February 28, 2008

By: __/Steven J. Sarussi/

Steven J. Sarussi Reg. No. 32784

McDonnell Boehnen Hulbert & Berghoff LLP 300 S. Wacker Drive Chicago, IL 60606 (312) 913-2136